Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;20(4):621-7.
doi: 10.1093/annonc/mdn682. Epub 2009 Jan 15.

Survival among women with triple receptor-negative breast cancer and brain metastases

Affiliations

Survival among women with triple receptor-negative breast cancer and brain metastases

S Dawood et al. Ann Oncol. 2009 Apr.

Abstract

Background: The purpose of this study was to determine the incidence of and survival following brain metastases among women with triple receptor-negative breast cancer.

Patients and methods: In all, 679 patients with nonmetastatic triple receptor-negative breast cancer diagnosed from 1980 to 2006 were identified. Cumulative incidence of brain metastases was computed. Cox proportional hazards models were fitted to explore factors that predict for development of brain metastases. Survival was computed using the Kaplan-Meier product limit method.

Results: Median follow-up was 26.9 months. In all, 42 (6.2%) patients developed brain metastases with a cumulative incidence at 2 and 5 years of 5.6% [95% confidence interval (CI) 3.8% to 7.9%] and 9.6% (95% CI 6.8% to 13%), respectively. A total of 24 (3.5%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 2 and 5 years of 2.0% (95% CI 2.6% to 6.0%) and 4.9% (95% CI 3.2% to 7.0%), respectively. In the multivariable model, no specific factor was observed to be significantly associated with time to brain metastases. Median survival for all patients who developed brain metastases and those who developed brain metastases as the first site of recurrence was 2.9 months (95% CI 2.0-7.6 months) and 5.8 months (95% CI 1.7-11.0 months), respectively.

Conclusion: In this single-institutional study, patients with nonmetastatic triple receptor-negative breast tumors have a high early incidence of brain metastases associated with poor survival and maybe an ideal cohort to target brain metastases preventive strategies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier plots illustrating survival and 95% confidence intervals among all 42 patients who developed brain metastases. Median survival for this group following a diagnosis of brain metastases was 2.9 months (95% confidence interval 2.0–7.6 months).
Figure 2.
Figure 2.
Kaplan–Meier plots illustrating survival among patients who developed brain metastases as the first site of recurrence and those who did not. Median survival among those who did and did not develop brain metastases as a first site of recurrence was 5.8 months [95% confidence interval (CI) 1.7–11 months] and 13.0 months (95% CI 11.4–17.6 months), respectively.

Comment in

References

    1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–752. - PubMed
    1. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667–2675. - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874. - PMC - PubMed
    1. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–7360. - PubMed
    1. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–2334. - PubMed

Publication types